Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
about
Chemogenomic approach identified yeast YLR143W as diphthamide synthetasePseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.Recent advances and novel treatment paradigms in acute lymphocytic leukemiaLoss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factorChemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityNovel agents for the treatment of childhood acute leukemia.Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.Antibody-based therapeutics for the treatment of human B cell malignanciesProtein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.Linked-in: design and efficacy of antibody drug conjugates in oncologyImmunotoxins: the role of the toxin.Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.Immunotoxins for leukemia.Targeting CD22 in B-cell malignancies: current status and clinical outlook.Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia.Current status of antibody therapy in ALL.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins.Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins.5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress
P2860
Q24304225-19A045A8-3752-4E1C-BB18-3AFE1443F7C0Q27323196-E45BB8D6-66A6-4029-8BC4-B3095A5B5A89Q28078076-BED10DC1-5AB2-4DAB-AECC-DA440B92CECEQ28266122-BB8B22CE-6959-4757-9E5B-B4B60B5BC9DDQ28553712-9CEB0D0B-C3D6-4C86-8D35-6ABA092AF9F4Q35189855-C6E68C99-3681-48C1-907A-83A3AAA590A3Q35192790-AC343B48-F9C3-4EC4-B014-A48AC506F636Q35214050-3F5A9CF3-DE9B-4CB9-876A-1CBC2F893CD4Q36796947-DFA7C9C8-38E0-4CD8-ABAC-97002BAF557DQ36907540-AFE21333-B790-43FE-8A9F-AC46ADE94523Q36917916-02D23A65-7946-4616-A0E4-EECADCFD8E87Q37029370-5B1A9294-EB0B-4640-8737-DFADA72461BEQ37139525-7DF750AA-B111-470D-ABBF-E48C78AC6F75Q37282218-066588A4-A69F-40BF-952B-A70D722AA224Q37709336-783DD974-40F6-46A9-A832-95AD44BA07AEQ38108568-99224920-651C-4080-BD1E-26B02406E944Q38141135-149C26FE-B26F-4D92-81CC-A9D7B0D0A008Q38266338-F5134C18-AE3A-43B6-A1B5-69366F1F616AQ38312596-736455F6-05ED-40A1-B156-B067B98DA8BFQ38434000-E988135D-B821-43FF-9E3B-8692798D639EQ41637417-3A272FD6-F04E-4454-9838-0D3DE39ED977Q42293412-F595326A-B93B-41B2-8D9B-D3AA724EFBEFQ46385489-A50A3A88-D8AD-4B15-9C51-8DB0E368395BQ47430608-B65A27D4-493E-42FE-BCC4-5494CE408E6AQ50063870-56E8C2D6-F9D6-4307-BBBE-95EF1278DC59Q57491820-0433BE7B-AB3A-4F72-98DC-0BC388E48DA3
P2860
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunotoxin resistance via rev ...... is a unique survival strategy.
@ast
Immunotoxin resistance via rev ...... is a unique survival strategy.
@en
type
label
Immunotoxin resistance via rev ...... is a unique survival strategy.
@ast
Immunotoxin resistance via rev ...... is a unique survival strategy.
@en
prefLabel
Immunotoxin resistance via rev ...... is a unique survival strategy.
@ast
Immunotoxin resistance via rev ...... is a unique survival strategy.
@en
P2093
P2860
P356
P1476
Immunotoxin resistance via rev ...... is a unique survival strategy.
@en
P2093
Alan S Wayne
David J FitzGerald
Ira Pastan
Laiman Xiang
Oleg Chertov
Tapan K Bera
P2860
P304
P356
10.1073/PNAS.1204523109
P407
P577
2012-04-16T00:00:00Z